Equities research analysts expect Prestige Consumer Healthcare Inc (NYSE:PBH) to announce $238.80 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Prestige Consumer Healthcare’s earnings. The highest sales estimate is $245.20 million and the lowest is $235.30 million. Prestige Consumer Healthcare reported sales of $255.97 million in the same quarter last year, which indicates a negative year over year growth rate of 6.7%. The business is expected to report its next quarterly earnings report on Thursday, May 9th.
On average, analysts expect that Prestige Consumer Healthcare will report full-year sales of $976.03 million for the current financial year, with estimates ranging from $970.00 million to $989.90 million. For the next year, analysts anticipate that the company will report sales of $964.78 million, with estimates ranging from $950.00 million to $982.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Prestige Consumer Healthcare.
Get Prestige Consumer Healthcare alerts:Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 7th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.02. Prestige Consumer Healthcare had a net margin of 6.44% and a return on equity of 11.85%. The business had revenue of $241.40 million during the quarter, compared to the consensus estimate of $241.40 million. During the same quarter last year, the company earned $0.70 earnings per share. The business’s quarterly revenue was down 10.8% compared to the same quarter last year.
A number of analysts have recently weighed in on PBH shares. DA Davidson raised their price target on shares of Prestige Consumer Healthcare to $38.00 and gave the stock a “neutral” rating in a research report on Monday, November 5th. ValuEngine raised shares of Prestige Consumer Healthcare from a “sell” rating to a “hold” rating in a research report on Wednesday, November 7th. Zacks Investment Research reissued a “hold” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, November 14th. Raymond James downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating and set a $28.40 price target for the company. in a research report on Tuesday, January 15th. Finally, Desjardins downgraded shares of Prestige Consumer Healthcare to a “hold” rating and set a $88.00 price target for the company. in a research report on Wednesday, February 13th. Two equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $45.48.
PBH stock opened at $28.52 on Tuesday. Prestige Consumer Healthcare has a twelve month low of $26.25 and a twelve month high of $41.76. The company has a debt-to-equity ratio of 1.49, a current ratio of 2.28 and a quick ratio of 1.34. The company has a market cap of $1.48 billion, a PE ratio of 11.05, a P/E/G ratio of 1.66 and a beta of 0.91.
A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in Prestige Consumer Healthcare by 410.0% in the fourth quarter. Millennium Management LLC now owns 135,193 shares of the company’s stock worth $4,175,000 after purchasing an additional 108,686 shares during the period. Macquarie Group Ltd. boosted its holdings in Prestige Consumer Healthcare by 17.6% in the fourth quarter. Macquarie Group Ltd. now owns 1,446,325 shares of the company’s stock worth $44,663,000 after purchasing an additional 216,570 shares during the period. Legal & General Group Plc boosted its holdings in Prestige Consumer Healthcare by 2.4% in the fourth quarter. Legal & General Group Plc now owns 52,367 shares of the company’s stock worth $1,618,000 after purchasing an additional 1,251 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Prestige Consumer Healthcare by 2.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 13,137 shares of the company’s stock worth $406,000 after purchasing an additional 347 shares during the period. Finally, Cipher Capital LP acquired a new position in Prestige Consumer Healthcare in the fourth quarter worth $737,000.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
See Also: Different Types of Derivatives
Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment